1
Chen Victor John, Dimarchi Richard D, Kriauciunas Aidas V, Smiley David L, Stucky Russell D: Glucagon-like insulinotropic peptide analogs, compositions, and methods of use. Lilly Co Eli, April 24, 1996: EP0708179-A2 (96 worldwide citation)

Glucagon-like insulinotropic peptide (GLP-1(7-37)) analogs and derivatives are disclosed. The analogs include amino acid substitutions, amino and carboxyl terminal modifications, and C6-C10 acylations. The claimed compounds stimulate the secretion or biosynthesis of insulin in poorly functioning bet ...


2
Day Jonathan, Patterson James, Chabenne Joseph, Dimarchi Maria, Smiley David, Dimarchi Richard D: Glucagon/glp-1 receptor co-agonists. Indiana Unversity Research And Technology Corporation, Day Jonathan, Patterson James, Chabenne Joseph, Dimarchi Maria, Smiley David, Dimarchi Richard D, ADDISON Bradford G, August 21, 2008: WO/2008/101017 (64 worldwide citation)

Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon ...


3
Dimarchi Richard D, Smiley David L, Dimarchi Maria, Chabenne Joseph, Day Jonathan, Patterson James, Ward Brian C: Glucagon/glp-1 receptor co-agonists. Indiana University Research And Technology Corporation, Dimarchi Richard D, Smiley David L, Dimarchi Maria, Chabenne Joseph, Day Jonathan, Patterson James, Ward Brian C, Addison Bradford G, December 23, 2009: WO/2009/155258 (53 worldwide citation)

Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting ...


4
Dimarchi Richard D, Smiley David L, Dimarchi Maria, Chabenne Joseph, Day Jonathan: Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers. Indiana University Research And Technology Corporation, Dimarchi Richard D, Smiley David L, Dimarchi Maria, Chabenne Joseph, Day Jonathan, Addison Bradford G, December 23, 2009: WO/2009/155257 (51 worldwide citation)

Modified glucagon peptides are disclosed having improved solubility and/or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The mod ...


5
Dimarchi Richard D, Smiley David L: Glucagon analogs exhibiting physiological solubility and stability. Indiana University Research And Technology Corporation, Dimarchi Richard D, Smiley David L, ADDISON Bradford G, May 18, 2007: WO/2007/056362 (49 worldwide citation)

Modified glucagon peptides are disclosed having improved solubility and stability, wherein the native glucagon peptide has been modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or both.


6
Dimarchi Richard D, de Arnab: Ester-based peptide prodrugs. Indiana University Research And Technology Corporation, Dimarchi Richard D, de Arnab, ADDISON Bradford G, August 13, 2009: WO/2009/099763 (48 worldwide citation)

Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., ...


7
DIMARCHI RICHARD D: Gip receptor-active glucagon compounds. INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Addison Bradford G, December 23, 2010: WO/2010/148089 (46 worldwide citation)

Glucagon peptides with increased GIP activity are provided, optionally with GLP-I and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein.


8
DIMARCHI RICHARD D: Amide based glucagon superfamily peptide prodrugs. INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Breen John P, June 24, 2010: WO/2010/071807 (45 worldwide citation)

Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the activ ...


9
DIMARCHI Richard D, KOU Binbin: Promédicaments peptidiques à base damides de la superfamille du glucagon, Amide based glucagon superfamily peptide prodrugs. Indiana University Research And Technology Corporation, DIMARCHI Richard D, KOU Binbin, ADDISON Bradford G, December 29, 2011: WO/2011/163012 (41 worldwide citation)

Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the activ ...


10
Dimarchi Richard D: Glucagon/glp-1 receptor co-agonists. INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Breen John P, June 23, 2011: WO/2011/075393 (38 worldwide citation)

Provided herein are glucagon analogs comprising a modified amino acid sequence of native human glucagon (SEQ ID NO: 2) that exhibit activity at the glucagon receptor, activity at the GLP-I receptor, or activity at each of the glucagon recpeotr and the GLP-I receptor. In some embodiments, the glucago ...



Click the thumbnails below to visualize the patent trend.